{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/management/recurrent-infection/","result":{"pageContext":{"chapter":{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection","depth":2,"htmlHeader":"<!-- begin field 53562fa7-2dbe-4d1f-8f31-848b5dfe1894 --><h2>Scenario: Recurrent infection</h2><!-- end field 53562fa7-2dbe-4d1f-8f31-848b5dfe1894 -->","summary":"Covers the management of women with recurrent vulvovaginal candidiasis (defined as four or more episodes in a year, with at least partial resolution of symptoms between episodes).","htmlStringContent":"<!-- begin item 2b2c96f6-1da2-456e-9554-c5ec6144fb0f --><!-- begin field 8739e161-56cb-4c13-9004-acbc0156a9c8 --><p>From age 12 years onwards (Female).</p><!-- end field 8739e161-56cb-4c13-9004-acbc0156a9c8 --><!-- end item 2b2c96f6-1da2-456e-9554-c5ec6144fb0f -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"63ce7f9f-a8fd-581f-9976-1c9313840d7e","slug":"managing-recurrent-infection","fullItemName":"Managing recurrent infection","depth":3,"htmlHeader":"<!-- begin field 8907a11a-2555-4b1e-b255-d4549c545e77 --><h3>How should I manage recurrent vulvovaginal candidiasis?</h3><!-- end field 8907a11a-2555-4b1e-b255-d4549c545e77 -->","summary":null,"htmlStringContent":"<!-- begin item 82ecedd8-62a8-4b9f-b362-b3c1664769ee --><!-- begin field a072b5ab-6240-4962-9967-e676663a8c56 --><ul><li><strong>If there is recurrent vulvovaginal candidiasis</strong> (defined as four or more documented episodes in 1 year, with at least partial resolution of symptoms between episodes):<ul><li><strong>Reassess </strong><strong>for <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/risk-factors/\">predisposing factors</a></strong> and remove or control as far as possible.</li><li><strong>Consider<em> </em></strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">alternative diagnoses</a><em>. </em></strong>If appropriate:<ul><li>Send a vaginal specimen for microscopy, culture, and sensitivity. This may identify a moderate/heavy growth of <em>Candida albicans</em>, non-albicans <em>Candida </em>species, or a <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">mixed infection</a>.</li><li>Consider measuring vaginal pH (if possible) to assess the likelihood of symptoms being due to <em>Candida </em>(pH less than or equal to 4.5), bacterial vaginosis (pH above 4.5), or <em>Trichomonas vaginalis </em>(pH above 4.5).</li><li>Arrange other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">investigations</a> as clinically indicated.</li></ul></li></ul></li><li><strong>Treat the presenting episode. </strong><ul><li><strong>Initially,</strong> prescribe an induction course of three doses of oral fluconazole 150 mg (to be taken 3 days apart) <em>or </em>an intravaginal antifungal for 10–14 days (according to response).</li><li><strong>Once the induction course is completed:</strong><ul><li>Give a prescription for 'treatment as required' (for example oral fluconazole 150 mg once a week or intravaginal clotrimazole 500 mg once weekly) to be used if symptoms recur, <em>or</em></li><li>Prescribe a maintenance regimen of 6 months' treatment with an oral or intravaginal antifungal (off-label use). Options include intravaginal clotrimazole 500 mg once a week, oral fluconazole 150 mg once a week, or oral itraconazole 50–100 mg daily.</li><li><strong>Review the woman after 6 months (or sooner if clinically indicated).</strong></li></ul></li><li><strong>The choice of treatment and formulation will depend on factors such as</strong> contraindications and cautions, the licenced age and indication for the product, and the person's preference.<ul><li><strong>For women aged 60 years and older, </strong>oral antifungals may be more acceptable because of the ease of administration.</li><li><strong>For breastfeeding women, </strong>intravaginal clotrimazole is recommended for both initial and maintenance treatment.</li></ul></li><li><strong>If there are vulval symptoms,</strong> consider prescribing a topical imidazole<em> </em>in addition to an oral or intravaginal antifungal. Options include:<ul><li>Clotrimazole 1% or 2% cream applied 2–3 times a day.</li><li>Ketoconazole 2% cream applied 1–2 times a day (for adults aged 18 years and older).</li></ul></li><li><strong>See the section </strong><strong>on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/\">Prescribing information</a> for detailed information on</strong> intravaginal, oral, and topical antifungals, including information on contraindications and cautions, adverse effects, and drug interactions.</li><li><strong>Be aware that</strong> intravaginal clotrimazole, oral fluconazole, and topical clotrimazole can be purchased over-the-counter.</li></ul></li><li><strong>Advise the woman on:</strong><ul><li>Measures to aid symptom relief and prevent recurrence. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/recurrent-infection/#general-advice-on-self-management\">Self-management advice</a> for more information. </li><li>How to manage any future episodes of vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/recurrent-infection/#general-advice-on-self-management\">Managing future episodes</a> for more information. </li></ul></li><li><strong>Do not routinely treat </strong><strong>an asymptomatic sexual partner.</strong><ul><li>If the male partner of a woman with vulvovaginal candidiasis has balanitis (characterized by erythematous areas on the glans of the penis, pruritus, and/or irritation), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/balanitis/\">Balanitis</a> for management information.</li></ul></li><li><strong>Refer or seek specialist advice if:</strong><ul><li>The person is aged 12–15 years old.</li><li>There is doubt about the diagnosis.</li><li>Symptoms are not improving and treatment failure is unexplained.</li><li>A non-albicans <em>Candida </em>species is identified.</li></ul></li></ul><!-- end field a072b5ab-6240-4962-9967-e676663a8c56 --><!-- end item 82ecedd8-62a8-4b9f-b362-b3c1664769ee -->","subChapters":[{"id":"e3cccdd1-fbb8-5b94-9969-d093baba0306","slug":"basis-for-recommendation-72f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4005cd67-2923-4f95-82b8-4085c906908e --><h4>Basis for recommendation</h4><!-- end field 4005cd67-2923-4f95-82b8-4085c906908e -->","summary":null,"htmlStringContent":"<!-- begin item 72f706b8-d80f-47b9-9615-6853010aff57 --><!-- begin field 4bf9a218-1992-419c-a2bf-90d944dbd709 --><h5>Reassessing for predisposing factors</h5><ul><li>CKS recommends reassessing for predisposing factors, as recurrence is more likely if there is continued exposure to predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li></ul><h5>Considering alternative diagnoses</h5><ul><li>The symptoms of vulvovaginal candidiasis are non-specific and may occur in women with other conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering alternative diagnoses if there is treatment failure, as misdiagnosis is a common cause for treatment failure.</li><li>The recommendations to send a vaginal specimen for microscopy, culture, and sensitivity and to consider measuring vaginal pH (if possible) are extrapolated from expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Treating the presenting episode </h5><ul><li><strong>Initial treatment</strong><ul><li>Expert opinion in the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> is that induction therapy ensures clinical remission (and is followed immediately by maintenance therapy) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li><li>For initial treatment, oral fluconazole or topical imidazole is recommended in the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>], a joint Faculty of Sexual and Reproductive Health Care (FSRH) and BASHH guideline on the <em>Management of vaginal discharge in non-genitourinary medicine settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Maintenance treatment</strong><ul><li>CKS recommends intravaginal clotrimazole, oral fluconazole, or oral itraconazole for maintenance treatment, as these have been assessed in clinical trials and are recommended in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]. In addition, oral fluconazole is licensed for reducing the incidence of recurrent vaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Evidence from randomized controlled trials (RCTs) suggests that maintenance treatment with weekly oral fluconazole, monthly oral itraconazole, or monthly intravaginal clotrimazole reduces rates of recurrence of vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel et al, 2004</a>].<ul><li>Recurrence rates increase when maintenance treatment is stopped, but in one trial important clinical benefits remained for at least 6 months for women who had used oral fluconazole.</li><li>In this trial, oral fluconazole was used for induction (150 mg for three doses followed by 150 mg once a week for 6 months) and approximately 90% of participants did not have a recurrence of vulvovaginal candidiasis after 6 months, and 40% after 1 year.</li></ul></li></ul></li><li><strong>Managing women aged 60 years and older</strong><ul><li>This recommendation is based on expert opinion in a review article, which states that after alternative diagnoses have been excludes and risk factors removed (where possible), the investigation and treatment of vulvovaginal candidiasis in older women should be the same as for younger women. However, oral regimens are perhaps more acceptable because of the ease of administration and the avoidance of potentially messy creams and suppositories [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nwokolo and Boag, 2000</a>].</li></ul></li><li><strong>Managing breastfeeding women</strong><ul><li>CKS recommends intravaginal clotrimazole as there is extensive experience with its use.</li><li>The manufacturer advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole, except for potentially life-threatening infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>], and itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Managing vulval symptoms</strong><ul><li>This recommendation is based on the BNF, which states that vaginal applications may be supplemented with a topical antifungal cream for vulvitis and to treat other superficial sites of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li></ul><h5>Not routinely treating an asymptomatic sexual partner</h5><ul><li>In the expert opinion of BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the available data do not support treating asymptomatic male partner of women with vulvovaginal candidiasis.</li><li>However, a small percentage of male partners will develop balanitis, and they should be managed appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul><h5>Referral or specialist advice</h5><ul><li>Vulvovaginal candidiasis is rare in pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Hayes and Creighton, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. CKS therefore recommends referral or seeking specialist advice for girls with recurrent infection.</li><li>The recommendation to arrange referral or seek specialist advice if non-albicans <em>Candida</em> species is identified is based on expert opinion in guidelines issued by the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which state that:<ul><li>The optimal treatment of non-albicans vulvovaginal candidiasis is currently unknown. Options include longer duration of treatment (7–14 days) with a non-fluconazole azole regimen (oral or topical) as first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>In some people with resistant organisms, treatments that should only be initiated by a specialist, or are difficult to obtain in primary care, may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li><li>The other recommendations on when to arrange referral or seek specialist advice are based on what CKS considers to be good clinical practice.</li></ul><h5>Treatments not recommended</h5><ul><li><strong>Oral ketoconazole</strong> — due to the increased risk of liver damage associated with its use, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013b</a>].</li></ul><!-- end field 4bf9a218-1992-419c-a2bf-90d944dbd709 --><!-- end item 72f706b8-d80f-47b9-9615-6853010aff57 -->","subChapters":[]}]},{"id":"fe39eeb4-1500-5800-8980-65b0e4383059","slug":"general-advice-on-self-management","fullItemName":"General advice on self-management","depth":3,"htmlHeader":"<!-- begin field c5cfb27f-0a36-497b-b7b1-6a20da086995 --><h3>What self-management advice should I give?  </h3><!-- end field c5cfb27f-0a36-497b-b7b1-6a20da086995 -->","summary":null,"htmlStringContent":"<!-- begin item b394d49f-f36e-44ad-9e0b-ab88538c5268 --><!-- begin field 260d5c50-6919-471b-948d-286acfdfb1d1 --><ul><li><strong>To aid symptom relief and prevent recurrence,</strong> <strong>advise the woman to:</strong><ul><li>Avoid the following potential predisposing factors:<ul><li>Washing and cleaning the vulval area with soap or shower gels (including those containing perfume and antiseptics [such as tea tree oil]), wipes, and 'feminine hygiene' products.</li><li>Cleaning the vulval area more than once a day.</li><li>Washing underwear in biological washing powder and using fabric conditioners.</li><li>Vaginal douching.</li><li>Wearing tight-fitting and/or non-absorbent clothing.</li></ul></li><li>Wash the vulval area with a soap substitute — this should be used externally and not more than once a day.</li><li>Use a simple emollient to moisturise the vulval area.</li><li>Consider using probiotics (such as live yoghurts) orally or topically to relieve symptoms.  </li></ul></li><li><strong>To manage any future episodes of vulvovaginal candidiasis, advise the woman that:</strong><ul><li>Intravaginal clotrimazole, oral fluconazole, and topical clotrimazole can be bought from pharmacies, but they should not be used long term without medical advice.</li><li><strong>Before using an over-the-counter (OTC) antifungal preparation,</strong> she should return for assessment by a healthcare professional if she:<ul><li>Is younger than 16 years or older than 60 years of age.</li><li>Is pregnant or breastfeeding.</li><li>Has abnormal or irregular vaginal bleeding, or a blood stained discharge.</li><li>Develops systemic symptoms.</li><li>Has symptoms that are not entirely consistent with a previous episode (for example the discharge is coloured or malodorous, or there are vulval or vaginal sores, ulcers, or blisters).</li><li>Has had two episodes of vulvovaginal candidiasis in the past 6 months, and has not consulted a healthcare professional about the condition for more than a year.</li><li>Has had a previous sexually transmitted infection (herself or her partner).</li><li>Has had a previous adverse reaction to an antifungal drug, or antifungal drugs have proved ineffective.</li><li>Is taking other drugs other than the contraceptive pill.</li><li>Has a liver or kidney disease, has had unexplained jaundice, or has any other chronic disease or illness.</li><li>Is experiencing lower abdominal pain or burning sensation on passing water.</li></ul></li><li><strong>After using an OTC antifungal preparation,</strong> she should return for assessment by a healthcare professional if her symptoms do not settle.</li></ul></li></ul><!-- end field 260d5c50-6919-471b-948d-286acfdfb1d1 --><!-- end item b394d49f-f36e-44ad-9e0b-ab88538c5268 -->","subChapters":[{"id":"7f93038d-f6b5-5fd8-9713-71aa256f1fbc","slug":"basis-for-recommendation-f58","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 759a435d-2470-4f24-816b-a4eae6ea47df --><h4>Basis for recommendation</h4><!-- end field 759a435d-2470-4f24-816b-a4eae6ea47df -->","summary":null,"htmlStringContent":"<!-- begin item f580955e-6677-41fb-9644-88a3107243f6 --><!-- begin field b24c7841-395a-4c5c-ae4a-1a6dae0ec005 --><h5>Aiding symptom relief and preventing recurrence</h5><ul><li><strong>Avoiding potential predisposing factors</strong><ul><li>Expert opinion in UK guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight-fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], although the evidence for these is limited, conflicting, or absent.</li><li>Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li></ul></li><li><strong>General care of the vaginal skin</strong><ul><li>The advice on the general care of vulval skin and the use of a simple emollient is based on expert advice in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of vulval skin disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCOG, 2011</a>].</li></ul></li><li><strong>Probiotics</strong><ul><li>The British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any randomized controlled trials (RCTs) comparing yoghurt containing <em>Lactobacillus acidophilus </em>with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li><li>One small RCT (n = 55) that compared oral <em>L acidophilus </em>with placebo at 1 month when given after a single dose of oral fluconazole (150 mg) found that oral <em>L acidophilus</em>:<ul><li>Decreased vaginal discharge compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 9/26 [35%] with placebo; P = 0.03).</li><li>Reduced the presence of yeast detected by culture compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 10/26 [39%] with placebo; P = 0.01).</li><li>There was no evidence of serious harm, but one systematic review (which did not identify any suitable RCTs) stated that oral yoghurt may cause gastrointestinal disturbance in people with lactose intolerance.</li></ul></li><li>The authors of the BMJ review concluded that the following should be considered:<ul><li>Applying yoghurt intravaginally may be embarrassing and uncomfortable for some women.</li><li>Although different yoghurts can be purchased, their compositions vary, and their effects may differ.</li><li>The effect of alterations in vaginal pH that may occur with intravaginal yoghurt use is unknown.</li></ul></li><li>CKS recommends advising the woman to consider using probiotics because although there is no evidence that they are effective, there is no evidence of (or concerns about) serious adverse effects.</li></ul></li><li><strong>Tea tree oil</strong><ul><li>The BMJ Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any RCTs comparing intravaginal tea tree oil with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One systematic review (which did not identify any suitable RCTs) stated that topical tea tree oil can cause skin irritation and a severe allergic rash.</li><li>One case report found that topical tea tree oil was associated with systemic hypersensitivity reaction.</li></ul></li><li>Expert opinion in the joint Faculty of Sexual and Reproductive Healthcare (FSRH) and the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>] and the joint Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group and BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>] is that there is currently insufficient evidence to recommend the use of tea tree oil in the management of vulvovaginal candidiasis.</li></ul></li></ul><h5>Managing future episodes of vulvovaginal candidiasis</h5><ul><li>These recommendations are based on advice in manufacturers’ Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016e</a>].</li><li>In addition, expert opinion in the US Centers for Disease Control and Prevention (CDC) guideline on <em>Vulvovaginal candidiasis</em> is that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]:<ul><li>Even women who have previously been diagnosed with vulvovaginal candidiasis are not necessarily more likely to be able to correctly diagnose themselves. Therefore, any woman whose symptoms persist after using over-the-counter (OTC) preparations or who has recurrence of symptoms within 2 months after treatment should be clinically evaluated and tested.</li><li>Unnecessary or inappropriate use of OTC preparations can lead to a delay in the treatment of other vulvovaginal conditions.</li></ul></li></ul><!-- end field b24c7841-395a-4c5c-ae4a-1a6dae0ec005 --><!-- end item f580955e-6677-41fb-9644-88a3107243f6 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}